Literature DB >> 6975387

Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen B-lymphocytes with plasmacytoma cells.

P De Baetselier, E Gorelik, Z Eshhar, Y Ron, S Katzav, M Feldman, S Segal.   

Abstract

The P3-NSI/1-Ag4-1 (NSI) plasmacytoma, when transplanted sc in syngeneic BALB/c mice, grows locally without forming spontaneous metastases. We tested whether somatic hybridization of the NSI cells with spleen B-lymphocytes would render them metastatic in (C57BL/6 X BALB/c) F1 mice. We found that the hybridomas thus produced generated spontaneous metastases with distinct organ specificities. Some hybridomas produced metastases in both liver and spleen, whereas others produced metastases in only the liver. Cells derived from spleen-and liver-seeking hybridomas, when transplanted sc, produced tumors that metastasized to both the liver and spleen. Tumor cells derived from spleen metastasis produced, on transplantation, a tumor that generated spleen metastasis of a larger mass than did tumors derived from liver metastases. Cells derived from liver-seeking hybridomas metastasized to only the liver. Similar patterns of organ specificity were observed after iv injection of the hybridoma cells. The spleen seemed to play determining role in controlling the production of liver metastases by hybridomas that produced both liver and spleen metastases. Such hybridomas did not produce liver metastases when injected into splenectomized recipients. Hybridomas that were only liver-seeking did produce metastases in splenectomized recipients.

Entities:  

Mesh:

Year:  1981        PMID: 6975387

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  22 in total

1.  Interaction of B-cell hybridomas with fibroblast or hepatocyte monolayers in vitro and their metastatic behaviour in vivo.

Authors:  S Verhaegen; H Verschueren; J Brissinck; D Van Hecke; D Dekegel; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

2.  Effect of cell fusion on metastatic ability of mouse hepatocarcinoma cell lines.

Authors:  Yan Ji; Mao-Ying Ling; Ying Li; Hong Xie
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

Review 3.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 4.  Quantitative genetic analysis of tumor progression.

Authors:  V Ling; A F Chambers; J F Harris; R P Hill
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 5.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 6.  Generation of phenotypic diversity and progression in metastatic tumor cells.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 7.  Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.

Authors:  P De Baetselier; E Roos; L Brys; L Remels; M Gobert; D Dekegel; S Segal; M Feldman
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  Melanoma x macrophage hybrids with enhanced metastatic potential.

Authors:  M Rachkovsky; S Sodi; A Chakraborty; Y Avissar; J Bolognia; J M McNiff; J Platt; D Bermudes; J Pawelek
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

9.  The role of the spleen in the organ-specific metastasis of murine BW 5147 T lymphomas.

Authors:  C Schmidt; H Verschueren; D Toussaint-Demylle; T van den Berg; G Kraal; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

10.  Sensitivity to thermochemotherapy of AKR lymphoma and B16 melanoma variants of malignancy.

Authors:  J Leibovici; G Klorin; M Huszar; S Hoenig; O Klein; M Michowitz; A Pinchassov
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.